# Treatment Options for Uterine Cancer
The treatment of uterine cancer depends heavily on the stage, histological type, molecular characteristics (including mismatch repair status and TP53 mutations), and the overall health of the patient. Below are the main treatment modalities, organized by phase and treatment group.
Surgical Removal
ProveniIncluded in official guidelines, or approved by EMA or FDA
Surgical removal of the uterus, fallopian tubes, and ovaries (total hysterectomy with bilateral salpingo-oophorectomy) is the standard treatment for uterine cancer in most stages. The procedure can be performed via traditional open surgery, laparoscopic (minimally invasive), or robot-assisted approach.
With laparoscopic or robot-assisted approach, patients typically recover faster than with open surgery, with less postoperative pain and shorter hospital stays. For patients with severe comorbidities (frailty), robot-assisted surgery may offer benefits, although differences in outcomes are modest. In advanced stages, removal of nearby lymph nodes may also be part of the procedure. This helps map the extent of the cancer and tailor further treatment.
General surgical risks apply to any operation: infection, blood loss, blood clots, and wound complications. The majority of patients recover well.
Pelvic Radiation
ProveniIncluded in official guidelines, or approved by EMA or FDA
After the uterus is removed, patients with certain risk factors (such as large tumor size, deep invasion into the uterine wall, or certain histological types) receive external radiation to the pelvis. This typically occurs over five to six weeks, with daily treatments.
The goal is to eliminate microscopic residual cancer in the pelvis and prevent cancer recurrence. The evidence for this effect is strong, particularly in intermediate-risk and high-risk tumors.
Side effects result from high doses of radiation to healthy tissue in the pelvis: fatigue, diarrhea, pain during urination, and sometimes long-term bowel or bladder disorders. These effects are usually limited by modern radiation techniques.
Internal Radiation (Brachytherapy)
ProveniIncluded in official guidelines, or approved by EMA or FDA
For certain tumors, internal radiation is also applied: a radioactive source is briefly placed in or near the cervix. This concentrates the dose at the site where cancer is most likely to recur.
Brachytherapy can be used alone or in combination with external radiation. It reduces the risk of local cancer recurrence.
The patient lies still during treatment; severe pain is uncommon, but discomfort is normal. Long-term side effects appear limited.
Chemotherapy
ProveniIncluded in official guidelines, or approved by EMA or FDA
In advanced, recurrent, or certain high-risk uterine cancers, chemotherapy is used, typically a combination of carboplatin (a platinum compound) and paclitaxel (a taxane). These substances disrupt the division of cancer cells.
Chemotherapy can be given before surgery (neoadjuvant) or after (adjuvant), and is sometimes combined with radiation or immunotherapy. In advanced disease, chemotherapy can also relieve symptoms and extend life.
Known side effects of this combination include: nausea, vomiting, hair loss, fatigue, infections due to a weakened immune system, nerve pain in hands and feet (neuropathy), and sometimes heart failure or kidney damage. Many side effects are manageable or temporary.
Hormone Therapy
ProveniIncluded in official guidelines, or approved by EMA or FDA
For certain slow-growing endometrial adenocarcinomas (particularly endometrioid type), hormone therapy—usually with progestins—can be used. These are hormones that inhibit the growth behavior of certain cancer cells.
Hormone therapy is mainly used in early stages, in patients who don't want or can't undergo surgery, or in advanced disease. The effect is usually less powerful than chemotherapy or radiation, but leads to less serious side effects.
Possible side effects include weight gain, hot flashes, and mood swings, although these vary greatly from person to person.
Immunotherapy
ProveniIncluded in official guidelines, or approved by EMA or FDA
Recent developments have established immunotherapy as a standard treatment for endometrial cancer, especially in tumors with mismatch repair deficiency (dMMR) or microsatellite instability. These substances—such as nivolumab and pembrolizumab—help the immune system better recognize and attack cancer cells.
Immunotherapy can be given before or after surgery, and is sometimes combined with chemotherapy or anti-angiogenic agents (see below). In advanced or recurrent cancer, immunotherapy can provide symptom relief and prolong survival.
Specific side effects of immunotherapy arise because the immune system can also attack healthy tissue (autoimmune-like effects): inflammation of the liver, kidneys, lungs, or intestines, and sometimes thyroid disorders. These reactions can be serious, but are usually manageable.
Anti-angiogenic therapy
ProveniIncluded in official guidelines, or approved by EMA or FDA
Bevacizumab is a substance that blocks the formation of new blood vessels in tumors, depriving the tumor of nutrients. This drug is increasingly given in combination with chemotherapy and immunotherapy, especially in advanced or TP53-mutated tumors.
Studies show that adding bevacizumab to a standard regimen can extend progression-free survival.
Side effects include high blood pressure, bleeding, blood clots, and sometimes problems with wound healing.
Targeted molecular therapy
ResearchediPositive results in clinical studies, not yet standard treatment
Research into targeted therapies—drugs aimed at specific genetic changes in tumor tissue—is actively underway. Studies are investigating drugs against mutations in KRAS, TP53, PTEN, and other genes. Research is also being conducted on effectiveness against certain protein markers (such as folate receptor-alpha and TROP2) on tumor cells.
These approaches are still mainly being applied in research settings and are not yet standard outside of studies. Patients with advanced disease may sometimes be invited to participate in studies testing these drugs in combination with chemotherapy or immunotherapy.
Side effects depend heavily on the specific drug and are not yet fully mapped out.
Tumor microbiome-targeted research
ResearchediPositive results in clinical studies, not yet standard treatment
Research suggests that the bacterial flora in and around tumors plays a role in how well immunotherapy works and how aggressively cancer behaves. Some studies are investigating whether modifying this microbiome (for example, through bacterial supplements or antibiotics) can improve response to treatment.
This is still experimental and not routinely used. Interpretation of results remains cautious.
Observation without direct treatment
ProveniIncluded in official guidelines, or approved by EMA or FDA
With very early, low-risk tumors (for example, FIGO stage IA, low-risk endometrioid type), watchful waiting—regular monitoring without immediate chemotherapy or radiation—can be a safe choice, especially after surgery. This prevents unnecessary side effects and reduces the risk of long-term radiation complications.
Regular follow-up visits (physical examination, ultrasound, tumor markers) remain essential to detect early recurrence.
Palliative care
ProveniIncluded in official guidelines, or approved by EMA or FDA
In advanced or recurrent cancer that can no longer be treated with surgery or radiation, treatments focus on symptom relief and quality of life. Chemotherapy, immunotherapy, or hormone therapy can relieve symptoms and slow progression, but do not cure the disease.
At the same time, pain, bleeding, constipation, and anxiety are actively treated. This approach is called palliative care and can be intensive medically, but is also increasingly focused on comfort and dignity as time passes.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._